Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.69 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.69 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.69 |
| ▸ | THRB | P10828 | 10/20 | 0.56 |
| ▸ | THRA | P10827 | 9/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787440 | 0.84 | THRB (0.75) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL1031799 | 0.84 | EGLN1 (0.69) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL2925489 | 0.84 | EGLN1 (0.62) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL29390250 | 0.82 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL522744 | 0.82 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL523089 | 0.82 | EGLN1 (0.66) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL522079 | 0.81 | EGLN1 (0.72) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL522017 | 0.81 | EGLN1 (0.72) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL29724635 | 0.81 | EGLN1 (0.72) | EGLN1BBOX1FTOTHRBTHRA | |
| SCHEMBL523155 | 0.80 | EGLN1 (0.71) | EGLN1BBOX1FTOTHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | EGLN1 238/4885BBOX1 292/4885FTO 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.